Virtual screening of 4855 FDA-approved drugs to target the domain-specific role of SRSF6 repurposed a β2-adrenergic receptor agonist indacaterol, which is approved for chronic obstructive pulmonary disease (COPD) treatment, for blocking SRSF6′s regulation on its downstream splicing targets, which suppresses colorectal cancer [48]. Here, SRSF6 is linked to chronic obstructive pulmonary disease.